Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C

被引：13

作者：

Fukuda, Kazuto ^{[1
]}

Imai, Yasuharu ^{[1
]}

Hiramatsu, Naoki ^{[4
]}

Irishio, Keiko ^{[2
]}

Igura, Takumi ^{[1
]}

Sawai, Yoshiyuki ^{[1
]}

Kogita, Sachiyo ^{[1
]}

Makino, Yuki ^{[1
]}

Mizumoto, Rui ^{[1
]}

Matsumoto, Yasushi ^{[1
]}

Nakahara, Masanori ^{[1
]}

Zushi, Sinichiro ^{[1
]}

Kajiwara, Nobuyuki ^{[3
]}

Oze, Tsugiko ^{[4
]}

Kawata, Sumio ^{[5
]}

Hayashi, Norio ^{[6
]}

Takehara, Tetsuo ^{[4
]}

机构：

[1] Ikeda Municipal Hosp, Dept Gastroenterol, Ikeda, Osaka 5638510, Japan

[2] Ikeda Municipal Hosp, Dept Clin Res, Ikeda, Osaka, Japan

[3] Ikeda Municipal Hosp, Dept Nephrol, Ikeda, Osaka, Japan

[4] Osaka Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Suita, Osaka, Japan

[5] Hyogo Prefectural Nishinomiya Hosp, Dept Internal Med, Nishinomiya, Hyogo, Japan

[6] Kansai Rosai Hosp, Dept Gastroenterol, Amagasaki, Hyogo, Japan

来源：

HEPATOLOGY RESEARCH | 2014年 / 44卷 / 12期

基金：

日本学术振兴会;

关键词：

chronic hepatitis C; peginterferon; renal impairment; ribavirin; telaprevir; VIRUS GENOTYPE 1B; INTERFERON; THERAPY; SAFETY; RESPONSES; HCV;

D O I：

10.1111/hepr.12229

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

AimRenal damage has been reported as an important complication during combination treatment of peginterferon (PEG IFN), ribavirin (RBV) and telaprevir (TVR) for chronic hepatitis C. However, very little is known about this complication. We investigated the role TVR plays in renal damage during this triple therapy. MethodsTwenty-five chronic hepatitis C patients with genotype 1 and high viral load received TVR in combination with PEG IFN and RBV for 12 weeks followed by treatment with PEG IFN and RBV. Renal function of these patients was prospectively evaluated for 16 weeks. ResultsCreatinine clearance decreased significantly during PEG IFN/RBV/TVR treatment. Consequently, serum creatinine and cystatin C significantly rose during PEG IFN/RBV/TVR treatment. Serum creatinine returned to pretreatment levels after the termination of TVR. The increase of serum creatinine and cystatin C from baseline significantly correlated with serum TVR level at day 7, which was determined by starting dose of TVR per bodyweight . When the patients were classified according to the starting dose of TVR per bodyweight, renal impairment was observed only in the high-dose (TVR 33mg/kg per day) group, not in the low-dose (TVR <33mg/kg per day) group. ConclusionThese results suggest that TVR dose per bodyweight is important for the occurrence of renal impairment in PEG IFN/RBV/TVR treatment.

引用

页码：1165 / 1171

页数：7

共 22 条

[1] Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels [J].

Akuta, Norio ;

Suzuki, Fumitaka ;

Kawamura, Yusuke ;

Yatsuji, Hiromi ;

Sezaki, Hitomi ;

Suzuki, Yoshiyuki ;

Hosaka, Tetsuya ;

Kobayashi, Masahiro ;

Kobayashi, Mariko ;

Arase, Yasuji ;

Ikeda, Kenji ;

Kumada, Hiromitsu .

JOURNAL OF HEPATOLOGY, 2007, 46 (03) :403-410

[2]

[Anonymous], 2013, Diabetes Care, V36, pS4

[3] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].

Chobanian, AV ;

Bakris, GL ;

Black, HR ;

Cushman, WC ;

Green, LA ;

Izzo, JL ;

Jones, DW ;

Materson, BJ ;

Oparil, S ;

Wright, JT ;

Roccella, EJ .

HYPERTENSION, 2003, 42 (06) :1206-1252

[4] Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection [J].

Enomoto, N ;

Sakuma, I ;

Asahina, Y ;

Kurosaki, M ;

Murakami, T ;

Yamamoto, C ;

Ogura, Y ;

Izumi, N ;

Marumo, F ;

Sato, C .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (02) :77-81

[5] Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C [J].

Hayashi, N. ;

Okanoue, T. ;

Tsubouchi, H. ;

Toyota, J. ;

Chayama, K. ;

Kumada, H. .

JOURNAL OF VIRAL HEPATITIS, 2012, 19 (02) :E134-E142

[6] Course and outcome of hepatitis C [J].

Hoofnagle, JH .

HEPATOLOGY, 2002, 36 (05) :S21-S29

[7] Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C [J].

Imai, Y ;

Kawata, S ;

Tamura, S ;

Yabuuchi, I ;

Noda, S ;

Inada, M ;

Maeda, Y ;

Shirai, Y ;

Fukuzaki, T ;

Kaji, I ;

Ishikawa, H ;

Matsuda, Y ;

Nishikawa, M ;

Seki, K ;

Matsuzawa, Y .

ANNALS OF INTERNAL MEDICINE, 1998, 129 (02) :94-99

[8] Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection [J].

Jacobson, Ira M. ;

McHutchison, John G. ;

Dusheiko, Geoffrey ;

Di Bisceglie, Adrian M. ;

Reddy, K. Rajender ;

Bzowej, Natalie H. ;

Marcellin, Patrick ;

Muir, Andrew J. ;

Ferenci, Peter ;

Flisiak, Robert ;

George, Jacob ;

Rizzetto, Mario ;

Shouval, Daniel ;

Sola, Ricard ;

Terg, Ruben A. ;

Yoshida, Eric M. ;

Adda, Nathalie ;

Bengtsson, Leif ;

Sankoh, Abdul J. ;

Kieffer, Tara L. ;

George, Shelley ;

Kauffman, Robert S. ;

Zeuzem, Stefan .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (25) :2405-2416

[9] The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects [J].

Kakuda, Hirokazu ;

Kanasaki, Keizo ;

Koya, Daisuke ;

Takekoshi, Noboru .

CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2013, 17 (02) :240-247

[10] Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death [J].

Kasahara, A ;

Tanaka, H ;

Okanoue, T ;

Imai, Y ;

Tsubouchi, H ;

Yoshioka, K ;

Kawata, S ;

Tanaka, E ;

Hino, K ;

Hayashi, K ;

Tamura, S ;

Itoh, Y ;

Kiyosawa, K ;

Kakumu, S ;

Okita, K ;

Hayashi, N .

JOURNAL OF VIRAL HEPATITIS, 2004, 11 (02) :148-156

← 1 2 3 →